Evidence of tumor progression at some point in the disease process may necessitate salvage radiation therapy, but one could also consider a longer treatment course than the 28-day course described in the trial, or retreatment with surgery or BRAF/MEKi which may result in continued disease control while sparing side effects of radiation. This evidence concerns the gene BRAF and neoplasm.